Obesity is expected to cost the UK economy billion per year when factoring in lost productivity, benefits, and wider societal impacts
What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
This degradation is catalyzed by the ubiquitous serum enzyme dipeptidyl peptidase 4 (DPP-4), which is produced both locally in the intestine and by circulating white blood cells
This means the drug does not hit peak levels and stay there permanently
33K Views 20 Posts $Eli Lilly and Co (LLY.US)$ reports first-quarter 2026 earnings on April 30, and this print will be less about whether demand for GLP-1 drugs is strong
Wegovy (Semaglutide for Obesity Treatment): Wegovy is the brand name for semaglutide, specifically formulated and approved for obesity treatment
